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ABSTRACT 
Purpose. To investigate the suitability of three antimicrobial peptides (AMPs) as cell-penetrating antimicrobial 
peptides. 
Methods. Cellular uptake of three AMPs (PK-12-KKP, SA-3 and TPk) and a cell-penetrating peptide 
(penetratin), all 5(6)-carboxytetramethylrhodamine-labeled, were tested in HeLa WT cells and analyzed by flow 
cytometry and confocal microscopy. Furthermore, the effect of the peptides on eukaryotic cell viability as well 
as their antimicrobial effect were tested. In addition, the secondary structure and disrupting ability of the 
peptides in the presence of bilayer membranes of different composition were analyzed. 
Results. AMP uptake relative to penetratin was ~13% (PK-12-KKP), ~66% (SA-3) and ~50% (TPk). All four 
peptides displayed a punctate uptake pattern in HeLa WT cells with co-localization to lysosomes and no 
indication that clathrin-mediated endocytosis was the predominant uptake mechanism. TPk showed the highest 
anti-bacterial activity. Only penetratin displayed clear secondary structure in the presence of membrane-
mimicking liposomes. SA-3 exhibited selective disruption of liposomes mimicking Gram-positive and Gram-
negative membranes. 
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Conclusion. PK-12-KKP is an unlikely candidate for targeting intracellular bacteria, as the eukaryotic cell-
penetrating ability is poor. SA-3, affected the cellular viability to an unacceptable degree. TPk showed 
acceptable uptake efficiency, high antimicrobial activity and relatively low toxicity, and it is the best potential 
lead peptide for further development. 
Key words: antimicrobial peptides; cell-penetrating peptides; antibiotics; Staphylococcus aureus; peptide-
membrane interaction. 
INTRODUCTION 
Cell-penetrating peptides (CPPs) are short, often cationic peptides capable of internalizing into eukaryotic cells 
without damaging the plasma membrane at effective internalization concentrations, and therefore they are 
actively pursued as potential drug delivery vehicles [1]. Cationic antimicrobial peptides (AMPs) comprise a class 
of peptides structurally similar to cationic CPPs, and AMPs constitute an essential part of the innate immune 
system in almost all living organisms [2]. Most known AMPs exert their antibacterial effect via selective 
membrane disruption thereby killing the bacteria, but also intracellular targets have been identified for some 
AMPs (e.g. buforin II [3], drosocin [4] and apidaecin [5]). The two peptide classes, cationic CPPs and cationic 
AMPs, share features such as: (i) a relatively short chain length (10–40 residues), (ii) a positive net charge, 
important for initial interaction with phospholipid membranes possessing an overall negative charge, and (iii) an 
amino acid composition with a significant content of non-polar residues considered to promote their interaction 
with, and in the case of AMPs, insertion into the hydrophobic core of the membrane bilayer [6]. The dominant 
biological effect of such highly cationic peptides may be altered from cell-penetrating to antimicrobial or vice 
versa by even small modifications of their sequence. Thus, examples of successful development of both AMP-
based CPPs (e.g. SynB1 [7] and Bac7 (15-24) [8]) and CPP-based AMPs (e.g. Pep-1-K) [9] have been reported. 
The increasing interest in the dual effects of these types of peptides has uncovered several examples of peptides 
exhibiting both eukaryotic cell membrane penetration and antimicrobial effects [10]. 
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During the last decade, a massive increase in community-associated and nosocomial multidrug-resistant 
Staphylococcus aureus infections has been registered, now reaching an alarming level; combined with a high 
rate of recurrent infections this poses a serious healthcare problem [11]. Increasing evidence infers that the high 
incidence of recurrent infections is caused by bacteria internalizing into epithelial cells at the site of infection 
[12]. Thus, complete eradication is not obtainable through treatment with commonly applied antibiotics [13]. We 
propose that development of a suitable cell-penetrating antimicrobial peptide could provide an alternative 
treatment regime against such persistent intracellular infections either in itself or as part of a combination 
therapy. In a previous study [14], we found that the well-characterized CPP, penetratin and a number of its 
analogs in fact possess antimicrobial properties. In the present study, we investigated whether bacteria-
penetrating AMPs could be applied as CPPs. 
Zhu and coworkers [9] showed that modification via Gly  Lys substitution in the synthetic CPP, Pep-1, 
afforded a designed AMP,  Pep-1-K (also denoted PK) that efficiently inhibited growth of both Gram-negative 
and Gram-positive bacteria. Further optimization towards a shorter analog was based on a 12 amino acid 
truncated version of PK with two lysine residues added to the C-terminus and three Thr Pro substitutions [15]. 
The resulting 14-mer PK-12-KKP displayed a more pronounced positive charge, low hydrophobicity, and only 
partial folding into a well-defined secondary structure due to the presence of the proline residues. Although the 
antimicrobial activity of PK and PK-12-KKP were comparable, their mode of action was indicated to be 
different as the latter exhibited a very low membrane depolarization of S. aureus similar to that of buforin 2 
known to have an intracellular target. Joshi and coworkers [16] reported a range of synthetic peptides designed 
from an amphipathic template displaying mainly hydrophobic and cationic amino acids. Amongst these, a 12-
mer peptide, SA-3 composed mainly of lysine and tryptophan, was found to exhibit efficient inhibition of both 
Gram-negative and Gram-positive bacteria as well as low hemolytic activity. Based on uptake of FITC-labeled 
peptide into E. coli and strong DNA binding properties of the peptide the authors suggested an internal target as 
the primary mode of action for SA-3 [16]. In addition, Zhu and co-workers reported that TPk, a peptidomimetic 
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analog of tritrpticin, displayed high activity against Gram-positive and Gram-negative bacteria as well as low 
cytotoxicity against eukaryotic cells [17]. The design of this analogue involved replacement of two proline 
residues with peptoid lysine residues (NLys), thereby increasing the overall molecular charge, while preserving 
the lack of amide protons required for hydrogen bonding to the backbone. Additionally, TPk depolarized the 
membrane potential of S. aureus to a low degree and only caused weak leakage of a fluorescent dye entrapped 
within negatively charged vesicles modeling the bacterial membrane. Confocal laser-scanning microscopy of 
bacteria exposed to FITC-labeled TPk showed clear accumulation of fluorescence in the cytoplasm, whereas the 
parent tritrpticin remained outside or associated to the cell membrane. These findings suggest that the mode of 
action for TPk involves inhibition of intracellular components after crossing the bacterial cell membrane.  
The common feature of the three AMPs selected for this study is that investigations of their bacterial killing 
mechanism have inferred that they act via intracellular targets. By applying advanced artificial membrane 
systems to study these peptides, we expect to gain a more thorough understanding of their effects on the 
membranes of both bacteria and eukaryotic cells.  
MATERIALS AND METHODS: 
Materials 
Reagents, resin and amino acid building blocks for solid-phase peptide synthesis were purchased from Iris 
Biotech (Merktredwitz, Germany) while DMF was acquired from VWR (Herlev, Denmark). Chemicals utilized 
were : 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (AppliChem, Darmstadt, Germany), Hanks 
Balanced Salt Solution (HBSS) (Gibco, Paisley, UK), 3-(4,5-dimethylthiazol-2-yl)- 5-(3-carboxy-phenyl)-2-(4-
sulphophenyl)-2H-tetrazolium (MTS) (Promega, Madison, WI, USA), phenazine methosulphate (PMS), sodium 
dodecyl sulfate (SDS), Eagle's minimal essential medium (EMEM), Triton X-100, calcein, 
diisopropylcarbodiimide (DIC), 1-hydroxybenzotriazole (HOBt), dimethylformamide (DMF) (all Sigma-
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Aldrich, Buchs, Switzerland), 5(6)-carboxytetramethylrhodamine (TAMRA) (Fluka, Buchs, Switzerland), 
DRAQ7® (Biostatus, Leicestershire, UK), Dulbecco's Modified Eagle Medium (DMEM) (Invitrogen, Paisley, 
UK) and phosphate buffered saline (PBS) (Invitrogen, Paisley, UK) Sephadex G-100 (GE Healthcare, Little 
Chalfont, UK), 2,2,2-trifluoroethanol (TFE) (Acros organics, Geel, Belgium) Mueller Hinton Broth (MHB) (BD, 
Le Pont de Claix, France). The lipids: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), cholesterol, 
1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (POPG), 1',3'-bis[1,2-dimyristoyl-sn-glycero-3-
phospho]-sn-glycerol (Cardiolipin 14:0; CL), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) were 
obtained from Avanti Lipids, Alabaster AL, USA.
Methods 
Solid phase peptide synthesis and labeling 
Peptide synthesis was performed by Fmoc-based solid-phase peptide synthesis (SPPS) employing a microwave-
assisted automated CEM Liberty synthesizer (CEM, Matthews, NC, USA); peptides were purified to >95% and 
90% for TAMRA-labeled peptides as described earlier [14]. For the fluorophore labeling, TAMRA (2.5 
equivalents) was used in a mixture of DIC (2.5 equivalents), and (HOBt; 2.5 equivalents) in (DMF) overnight at 
room temperature. The identity of the peptides was confirmed by HRMS spectra obtained by using a Bruker 
micrOTOF-Q II Quadropol MS detector; analyses were performed as ESI-MS (m/z): [M + nH]
n+
 (Bruker, 
Bremen, Germany). An overview of the synthesis products can be found in Table I. 
Cell culture  
HeLa WT cells from the American Type Culture Collection (ATCC, Manassas, VA, USA) were maintained in 
EMEM supplemented with 10,000 IU/mL penicillin, 10 mg/mL streptomycin, 2 mM L-glutamine, 0.1 mM non-
essential amino acids (all from Sigma-Aldrich, St. Louis, MO, USA), 1 mM sodium pyruvate (Invitrogen, 
Carlsbad, CA, USA), and 10% (v/v) fetal bovine serum (FBS) (Fisher Scientific, Waltham, MA, USA). Cells 
were kept under tissue culture conditions ( 5% CO2, 37°C) and detached from culturing flasks at 80% confluency 
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by treatment with trypsin-EDTA, and subsequently subcultured once weekly. For the MTS/PMS assay HeLa WT 
cells were seeded at a density of 30,000 cells/cm2 in flat-bottomed 96-well Plates (Corning Costar, Sigma-
Aldrich, Brøndby, Danmark). NIH 3T3 cells for MTS/PMS assay were acquired from ATCC (Manassas, VA, 
USA), maintained in DMEM supplemented with 10% (v/v) newborn calf serum (NCS) (Gibsco, Paisly, U.K.), 
10,000 IU/mL penicillin, 10 mg/mL streptomycin and 2 mM L-glutamine and seeded in a flat-bottomed 96-well 
Plates (Corning Costar, Sigma-Aldrich, Brøndby, Danmark) at a density of ~69,000 cells/cm
2
. HUVEC cells 
were acquired from the European Collection of Cell Cultures (ECACC) (Salisbury, U.K.) and maintained in 
Ham’s F-12K (Kaighn’s) medium supplemented with 10% (v/v) FCS, 0.1 mg/mL heparin, 0.03 mg/mL 
endothelial cell growth supplement as well as 10.000 IU/mL penicillin, 10 mg/mL streptomycin and 2 mM L-
glutamine and seeded in a flat-bottomed 96-well Plates (Corning Costar, Sigma-Aldrich, Brøndby, Danmark) at 
a density of ~47,000 cells/cm
2
. HeLa WT cells for confocal microscopy visualization were cultured on (poly-D-
lysine)-coated, 35 mm imaging dishes (MatTek Glass Bottom Microwell Dishes, MatTek, Ashland, MA, USA) 
at a density of ~140,000 cells/cm
2
 and for flow cytometry cells were seeded at a density of 110,000 cells/cm2 in 
12-well plates (NUNC, Roskilde, Denmark). For all experiments, the cells were cultured for 22-24 h to obtain a 
subconfluent cell monolayer (confluency 80-90%).  
MTS/PMS viability assay 
The cells were washed twice with 37°C HBSS supplemented with 10 mM HEPES (hHBSS) and exposed to 100 
ȝL of peptide solution in hHBSS (concentration range 1–256 ȝM) for 1 h under tissue culture conditions. A 
0.2% (w/v) SDS solution and hHBSS were used as positive (ODpos.ctrl) and negative (ODneg.ctrl) control, 
respectively. The peptide solution was removed by inverting and gently tapping the back of the plate. 
Subsequently, a mixture of 240 ȝg/mL MTS and 2.4 ȝg/mL PMS in test buffer was applied. The plate was 
incubated shielded from light (37°C, 50 rpm) for approx. 2 h until the cells exposed to buffer (the negative 
control) reached an absorbance of 1. Absorbance was measured on a POLARstar Optima (Ȝ = 492 nm) (GMB 
Labtech, Offenburg, Germany). The relative cell viability (%) was calculated according to Eq. (1):  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
7 
(1)  Viability (%) = (ODpeptide–ODpos.ctrl.) / ODneg.ctrl.–ODpos.ctrl.
Confocal laser-scanning microscopy (CLSM) 
The cells were rinsed with DMEM supplemented with 10% (v/v) heat-inactivated fetal calf serum, 100 IU/mL 
penicillin and 100 µg/mL streptomycin (37°C). The medium was replaced with 200 ȝL of 10µM TAMRA–
labeled peptide in PBS and incubated for 1 h under tissue culture conditions. Subsequently, the test solutions 
were discarded, the cells washed twice with DMEM, once with imaging medium (DMEM without phenol red), 
and finally resuspended in 300 µL of imaging medium containing 0.3% (v/v) DRAQ7®. Immediately hereafter, 
CLSM was performed using an inverted Leica SP5 confocal laser-scanning microscope (Leica Mikrosystems, 
Wetzlar, Germany) equipped with an Ar and HeNe laser and a 63× 1.4 NA oil immersion objective. Live-cell 
microscopy was performed at room temperature and with a fixed instrument configuration across all samples. 
Furthermore, endocytosis pathway markers: dextran and transferrin were applied: In lysosome labeling 
experiments the cells were incubated with 0.1 mg/mL 10 kDa dextran Alexa Fluor® 647 (Life Technologies, 
Basel, Switzerland) for 210 min, and the label subsequently chased into lysosomes via a further incubation in 
dextran-free medium for 20 h, after which the cells were incubated with peptide as described above. To 
investigate uptake by clathrin-mediated endocytosis, the cells were incubated for 50 min with 100 nM transferrin 
Alexa Fluor® 647 (Life Technologies, Basel, Switzerland), rinsed with Complete DMEM. PBS 100 nM 
transferrin Alexa Fluor® 647 was supplemented with TAMRA- peptides (200 µL) at various concentrations and 
incubated under tissue culture conditions for 10 min before proceeding with the washing and imaging procedure 
stated above. 
Flow cytometry 
Cellular internalization of TAMRA-labeled peptides was quantified by flow cytometry. Initially, the cells were 
washed once with 1 mL PBS (37°C), containing 10 µM peptide solution (700 µL in PBS) and incubated for 1 h 
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under tissue culture conditions. The cells were subsequently rinsed three times with ice-cold PBS. Detachment 
of the cells from the wells was done by addition of 0.01 % (w/v) trypsin-EDTA (200 µL, 10 min, 37°C, 5% 
CO2), and after centrifugation (5 min, 1076  g) the cells were washed twice with ice-cold PBS containing 10% 
(v/v) FBS. Lastly, the cells were resuspended in 500 µL PBS with 10% (v/v) FBS containing 0.3% (v/v) 
DRAQ7®. Flow cytometry analysis was performed shortly after the preparation by using a Gallios flow 
cytometer (Beckman Coulter, Fullerton, CA, USA). The fluorescence mean of 10,000 viable cells was recorded 
gating for forward and sideways scattering as well as for DRAQ7® fluorescence intensity. 
Minimal inhibitory concentration (MIC)  
The inhibitory effect of peptides on bacterial growth was determined by micro dilution broth assay according to 
Clinical Laboratory Standard Institute (CLSI) guidelines [19]. The peptides were assayed against S. aureus 
(ATCC 25923) and E. coli (ATCC 25922) in the dilution range 1-128 µM in MHB (experiments performed in 
triplicate on at least two separate days). The bacteria were inoculated to 5 × 10
5
 CFU/mL and incubated at 35°C 
in ambient air for 18 h, after which the MIC values were determined as the lowest concentration showing no 
visible growth as compared to the control without antibacterial compound added. 
Liposome preparation 
Liposomes were prepared by using a procedure previously described [14]. In brief, large unilamellar vesicles 
(LUV) were prepared from POPC and cholesterol in a molar ratio of 10:1 in order to mimic an eukaryotic cell 
membrane composition [20–22], while a liposome composition with POPG and synthetic CL in a molar ratio of 
3:1 was used to mimic Gram-positive S. aureus membrane composition [20–22]. POPG, CL, and DOPE in a 
molar ratio of 2:7:1 were employed as a model for Gram-negative Escherichia coli membranes [20–22]. For 
liposomes, the lipid film was dispersed in Tris buffer (10 mM, pH 7.4), whereas calcein-loaded liposomes were 
formed in Tris buffer (10 mM, pH 7.4) containing 150 mM NaCl, 0.1 mM EDTA and 70 mM calcein. Excess 
calcein was removed by passing the liposomes through a Sephadex G-50 column. 
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Circular dichroism (CD) spectroscopy  
CD spectra were measured as previously described [14]. In brief, peptide and liposomes were added to a quartz 
cell with 1 mm light path, and 5 consecutive scans were collected in the range 190–260 nm. The scans were 
averaged and the background contribution from buffer or liposome-containing buffer was subtracted. An Olis 
DSM 10 spectrophotometer (Olis, Bogart, GA, USA) was used for all measurements except the measurements 
with the POPG:CL:DOPE (2:7:1 molar ratio) which was performed on a J-815 CD spectrometer (Jasco, Easton, 
MD, USA). 
Calcein release assay 
To measure leakage from calcein-loaded liposomes, these were added to black 96-well plates (MicroWell 96 
optical bottom plates, NUNC, Roskilde, Denmark) at a concentration of 1.2 ȝM lipid determined from the 
strongest fluorescent signal from the lysed calcein-containing vesicles in a volume of 180 ȝL. The fluorescence 
was monitored by utilizing a FLUOstar OPTIMA plate reader (GMB Labtech, Offenburg, Germany) at an 
excitation wavelength of 485 nm and an emission wavelength of 520 nm to determine F0. A volume of 20 ȝL of 
peptide solution was added and measurement of calcein leakage was initiated within 10 sec from the first 
addition of peptide, and the peptide-induced calcein leakage was recorded for a period of 680 sec (340 sec for 
PK-12-KKP with POPG/CL liposomes) in order to determine F. Subsequently, the liposomes were disrupted 
completely by addition of 20 µL 20% (v/v) Triton X-100, and then the signal from the total amount of calcein 
was recorded (Ft). The relative release was calculated according to Eq. (2): 
(2) Calcein leakage [%] = [(F−F0)/(Ft−F)0]100%  
Data analysis 
Results are presented as the mean of three measurements ±SD, and unless otherwise stated experiments were 
performed in triplicate. Statistical significance was determined by the students t-test where P<0.05 is considered 
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significant. For the viability assays the 50% cellular viability (EC50) was estimated by using Prism 6 for Mac OS 
X vs. 6.0 and by non-linear regression according to Eq. (3): 
(3) Y = Bottom + (Top-Bottom)/(1 + (X/EC50)(-HillSlope)). 
RESULTS  
In the present study, three AMPs (PK-12-KKP, SA-3 and TPk) and a CPP (penetratin) were investigated with 
respect to their: (i) ability to internalize into eukaryotic cells, (ii) subcellular localization inside eukaryotic cells, 
(iii) ability to inhibit bacterial growth, (iv) influence on eukaryotic cell viability, and (v) interaction with 
different membrane models. 
Uptake of short cationic AMPs and CPP in HeLa WT cells  
To determine whether the three AMPs were capable of internalizing into eukaryotic cells, TAMRA-labeled 
variants of the peptides were used. The uptake efficiency of the three AMPs was compared to that of the 
similarly labeled well characterized CPP, penetratin. As expected, penetratin displayed a higher total cellular 
uptake as compared to the AMPs as determined by flow cytometry (Figure 1). The Pep-1 derived analog PK-12-
KKP displayed a significantly lower uptake (10% relative to penetratin) than the other compounds tested 
(P<0.01). SA-3 showed the highest uptake as compared to the other tested AMPs reaching a level of 65% of the 
uptake of penetratin, which was significantly better than that of TPk (P<0.05). TPk exhibited intermediate 
uptake efficiency with about half the uptake found for penetratin.  
Intracellular distribution and co-localization with endocytosis pathway markers 
Microscopical analysis confirmed the flow cytometry data showing that the TAMRA-labeled variants of the 
AMPs and penetratin gave rise to significant uptake resulting in subcellular punctate distribution patterns 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
11 
throughout the cytoplasm of the HeLa WT cells without affecting the viability of the cells (data not shown) as 
determined by addition of DRAQ7
®
; a DNA binding dye that selectively stains dead and permeabilized cells. 
Peptide uptake was also imaged in cells that first were stained with fluorescently labeled pulse/chased 10 kDa 
dextran that accumulates in lysosomes. As expected peptide incubations in lysosome-labelled cells for the four 
peptides gave rise to punctate fluorescent structures (Figure 2), and in the case of PK12-KKP and penetratin 
there was clear evidence of delivery to lysosomes manifested as co-localization with dextran fluorophore. 
Whether clathrin-dependent endocytosis of the peptides occurred to a significant extent was studied by testing in 
cells that were pre-incubated with fluorescent transferrin present in the media during these short peptide 
incubations. This resulted in an overall low uptake of PK-12-KKP with no discernible co-localization with 
transferrin suggesting that clathrin-mediated endocytosis is not utilized by the peptide. With respect to 
transferrin there was minimal co-localization with SA-3 and TPk, however, these cells also showed diffuse 
cytosolic staining. Penetratin localization was confined to punctate structures that did not overlap to any extent 
with transferrin. For all four peptides DRAQ7
®
 positive cells were not observed indicating that at this 10 µM 
concentration the plasma membrane was not compromised to a degree that resulted in leakage of the dye to label 
nuclear DNA. 
Cellular viability and antimicrobial effect 
To assess the relative effects of the peptides on eukaryotic cell viability and bacterial growth, the results of the 
tetrazolium dye-based viability assay MTS/PMS and the determined minimal inhibitory concentration on S. 
aureus were compared. To gain insight regarding a possible selectivity of the peptides towards specific 
eukaryotic cells, the viability of HeLa WT cells as well as of fibroblast cells (NIH 3T3) and human umbilical 
vein endothelial cells (HUVEC) in the presence of the three AMPs and penetratin was investigated (Table II). 
No significant reduction in viability of all three cell lines upon exposure to PK-12-KKP was detected within the 
concentration range tested (i.e. up to 256 ȝM). By contrast, cell viability was severely lowered by SA-3 with 
EC50 values against HeLa WT and NIH 3T3 cell lines at concentrations 25-30 ȝM. HUVEC cells were generally 
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much less sensitive to the peptides, and SA-3 was the only peptide that affected these cells at the tested 
concentrations. TPk reduced the viability of HeLa WT cells with an EC50 value only slightly higher than that of 
SA-3, however, its cytotoxicity against NIH 3T3 cells was at least four times lower than that of SA-3. Also, for 
penetratin no significant decrease in cell viability of any of the cell lines was observed within the tested 
concentration range. Table II shows that overall, the antimicrobial activity of the AMPs was more pronounced 
towards the Gram-negative E. coli than against the Gram-positive S. aureus, and that TPk was the most effective 
AMP.  
Membrane interactions 
The folding behavior of the four peptides was examined by circular dichroism (CD) spectroscopy in the presence 
of liposomes at a peptide to lipid molar ratio of 1:100; a ratio that was previously used to successfully study CPP 
secondary structure in the presence of unilamellar vesicles [23]. Different liposome compositions were employed 
in order to investigate interactions with specific types of membranes. As a model for Gram-positive bacteria 
membranes POPG:CL liposomes at a molar ratio of 3:1 (70.0 nm, PdI < 0.1) was utilized, while for Gram-
negative bacterial membranes POPG:CL:DOPE liposomes at a molar ratio of 2:7:1 (80.84 nm, PdI < 0.1), and 
for eukaryotic cell membranes POPC:cholesterol liposomes at a molar ratio of 10:1 (75.9 nm, PdI = 0.1), 
respectively, were employed.  
The CD spectrum of the proline-rich PK-12-KKP (Figure 3a) displayed uncharacteristic spectra in the presence 
of all liposomal model membranes and in 90:10 (v/v) TFE-water, and thus no specific secondary structure of 
PK-12-KKP could be deduced. SA-3 appeared to possess some degree of α-helicity in 90% TFE with minima 
around 208 nm and 222 nm. The minimum at 222 nm was also observed in the presence of both POPG:CL and 
POPC:cholesterol liposomes, although it was more distinct for the latter. In the presence of both of these 
liposomal membrane variants, the 208 nm minimum flattens out (Figure 3b). TPk showed almost no variation in 
the secondary structure upon interaction with different liposomal model membranes as well as in 90% TFE. Due 
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to the small changes in the CD spectra, it was not possible to assign any change in specific secondary structure 
by analysis of the spectra obtained for TPk (Figure 3c). Penetratin exhibited a highly variable secondary 
structure depending on the different model membranes (Figure 3d). The CD spectrum of penetratin recorded in 
90% TFE corresponds to a classical α-helix conformation with minima at 208 nm and 222 nm along with a 
positive ellipticity in the range below 200 nm. In the presence of POPG:CL liposomes, penetratin seems to adopt 
an antiparallel β-sheet-like secondary structure with a minimum just below 220 nm and a maximum around 200 
nm, while in the presence of the POPG:CL:DOPE liposomes no unambiguous secondary structure was observed. 
However, in the presence of POPC:cholesterol liposomes penetratin remained unstructured. 
Calcein-containing liposomes of the same compositions as described above were exposed to varying peptide 
concentrations and the change in fluorescence over time was measured in order to assess both the degree and the 
kinetics of the membrane disruption induced by the peptides. The liposomes prepared with calcein displayed 
monomodal size distributions, yet overall they displayed a slightly smaller size than the ones without calcein; 
namely POPG:CL (molar ratio 3:1, 48.8 nm, PdI = 0.3), POPG:CL:DOPE (molar ratio 2:7:1, 51.6 nm, PdI = 0.2) 
and POPC:cholesterol (molar ratio 10:1, 39.1 nm, PdI < 0.1). When comparing the specific model membranes, 
clear differences were found regarding the maximal amount of calcein released upon exposure to the three 
peptides for up to 680 sec (Table III). Considering the individual peptides, PK-12-PPK gave rise to a low partial 
calcein leakage of 13-25 % for all three liposomal compositions. Overall, SA-3 resulted in a higher relative 
leakage, but with a higher degree of selectivity towards the liposomes modeling the bacterial membranes. Thus, 
SA-3 induced a high relative leakage (82% to completion) from the bacteria-mimicking liposomes, whereas the 
eukaryotic model liposomes only released 33% of the encapsulated calcein at the same peptide concentration. 
TPk had only a minimal effect on the POPG:CL:DOPE (2:7:1) liposomes mimicking the E. coli membrane as 
only 3% of the calcein was released. In contrast, TPk disrupted both POPG:CL (3:1) liposomes mimicking S. 
aureus membranes and liposomes corresponding to a mammalian membrane composition releasing more than 
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30% of the encapsulated calcein. Penetratin exhibited a selective disruption of the S. aureus model liposomes 
with low disruptive capacity for the other two liposome compositions.
More detailed insight into the effects of SA-3 and penetratin on the different model membranes was gained by 
depicting comparative time-resolved and concentration-dependent profiles (Figure 4). The release of calcein 
from POPG:CL liposomes triggered by SA-3 is immediate, as the first measurement in the presence of 1.6 ȝM 
peptide showed 20% calcein release (Figure 4). For penetratin, a slow initial calcein release was observed with 
a lag period of 40 sec, however, after 10 min full liposomal disruption was observed, while SA-3 reached a total 
release of 82%. Inspection of the concentration-dependent release of calcein from the POPG:CL model 
membranes revealed that these vesicles are more sensitive to penetratin than to SA-3 over the entire 
concentration range, even though the initial release rate is more rapid for SA-3.  
DISCUSSION 
The peptides investigated in this study have previously been tested for their antibacterial activity [15–17], 
whereas the objective of the current study was to assess their potential to target bacteria internalized in 
eukaryotic host cells. Quantification of the cellular uptake of the peptides allowed a ranking of these sequences 
according to their internalization efficiency in comparison to that of penetratin, a well-characterized CPP that has 
previously been shown to internalize efficiently into several eukaryotic cell lines [24,25] including HeLa WT 
cells [26]. Further, the distribution pattern of the AMPs in HeLa WT cells was assayed by confocal microscopy 
with and without fluorophore-labeled dextran as an endocytic probe that can be used to label the entire 
endolysosomal pathway or specifically lysosomes [27], which under the applied experimental conditions 
accumulate in the late vacuolar system, particularly in the lysosomes. Fluorophore-labeled transferrin known to 
be taken up by clathrin-dependent endocytosis [28] was included to investigate a potential contribution to the 
uptake via this pathway. Expectedly, penetratin showed a punctate uptake pattern with some co-localization with 
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dextran, and no or poor co-localization with transferrin indicating that its uptake is not receptor-mediated. This 
confirms earlier reports supporting a non-receptor mediated endocytosis of penetratin [29]. Although reports 
have indicated that direct translocation [30] or clathrin-dependent endocytosis are responsible for penetratin 
uptake [31], this was not evident under the conditions applied in the present study. It has also been debated that 
penetratin uptake most likely involves a combination of direct translocation and endocytotic pathways, while the 
dominant mechanism seems to be highly dependent on the specific experimental conditions [32].
The secondary structure of the peptides in the presence of three different liposomal compositions was examined 
by CD spectroscopy. Penetratin showed a classical α-helical conformation in TFE-water 90:10, but in the 
presence of POPG:CL:DOPE (molar ratio 2:7:1) liposomes mimicking the membrane of E. coli it did not show 
any clear secondary structure, however, its CD spectrum might represent a mix of partial -helix and -sheet 
conformations. To determine the influence of the peptides on immediate cell toxicity [8], various cell lines were 
exposed to the peptides, and their viability determined. Penetratin showed no impact on cell viability within the 
tested concentration range in accordance with our earlier findings [14]. A general trend was that HeLa WT cells 
were more sensitive towards the tested compounds as compared to the HUVEC and NIH 3T3 cells. This is in 
accordance with earlier observations on the membrane toxicity of short cationic AMP mimics towards various 
cell lines [33]. 
The propensity of penetratin to adopt an α-helical conformation while interacting with membranes mimicking 
eukaryotic cells was very low in disagreement with earlier findings [14]. This confirms that the presence of 
POPG is important for induction of secondary structure in penetratin corroborating earlier studies demonstrating 
that unstructured penetratin conformations are predominant in the presence of purely PC-based lipid systems
[22]. To test the effect of the peptides on the integrity of different model membranes the corresponding 
liposomes containing a self-quenching solution of calcein were prepared and exposed to the AMPs and CPP.
Penetratin showed negligible calcein release from the model liposomes mimicking eukaryotes and E. coli (8% 
and 13% release, respectively), whereas complete disruption of the liposomes mimicking S. aureus membranes 
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indicated selectivity toward this membrane model composition. Interestingly, in the bacterial inhibition assay, 
penetratin showed a stronger inhibition of E. coli than of S. aureus, indicating a mode of action against E. coli 
other than simple membrane disruption. The MIC values were within the range of earlier findings for penetratin 
[14,34–36].  
Surprisingly, the amount of PK-12-KKP taken up by HeLa WT cells was significantly less than that seen for 
penetratin even though its design is based on a CPP template. Apparently, the modifications of the CPP aimed at 
conferring antimicrobial properties to the analogue concomitantly reduced its capability for eukaryotic 
internalization. Visualization of cell uptake by confocal microscopy showed that despite relatively low 
internalization of PK-12-KKP, some intracellular presence was clearly detectable. The peptide exhibited a 
punctate uptake pattern that showed some co-localization with internalized dextran, indicating uptake by 
endocytosis and trafficking of the peptide to the late stages of the endocytic pathway. No co-localization with 
transferrin was observed, suggesting that uptake is not mediated via clathrin-coated endocytosis. To understand 
the initial peptide-membrane interaction, PK-12-KKP was investigated by CD spectroscopy in the presence of 
the three different model membranes, and the spectra of the peptide in all cases indicated a very high presence of 
unstructured conformations confirming earlier studies done in SDS micelles [15]. Since secondary structure (e.g. 
-helical folding) often has been shown to be a prerequisite for efficient CPP uptake [37,38], the primarily 
unstructured conformation of PK-12KKP is a plausible cause of its low uptake. Exposure of mammalian cells to 
PK-12-KKP only gave rise to a minor negative effect on their viability indicating low affinity for eukaryotic 
membranes in accordance with its low propensity for internalization. Interestingly, induction of dye leakage 
from the calcein-containing liposomes by PK-12-KKP only differed slightly between the three liposomal 
compositions implying a lack of bacteria-specific membrane disruption. Despite this fact, the potency of PK-12-
KKP was modest (MIC of 32 µM and 16-32 µM against S. aureus and E. coli, respectively) deviating 
significantly from an earlier investigation of its antimicrobial activity with a MIC of 2 µM against both S. aureus
(KCTC 1621) and E. coli (KCTC 1682) tested in a low-nutrition 1% (w/v) peptone solution [15], which has been 
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shown to drastically diminish bacterial survivability [39]. However, as the present MIC determinations were 
performed in MHB according to CLSI recommendations [19], this may explain the observed discrepancies. 
Overall, the low uptake of PK-12-KKP into eukaryotic cells combined with a modest antibacterial activity do not 
favor a potential application in targeting intracellular bacteria. 
SA-3 is a synthetic designed AMP that showed the highest cellular uptake of the three investigated AMPs, most 
likely due to its high content of both cationic and hydrophobic residues; this feature is known to facilitate CPP 
uptake [40]. Furthermore, the peptide displays a slight propensity for adopting an -helical secondary structure 
that also may promote cellular internalization. The intracellular distribution of SA-3 was punctate, and thus 
similar to that seen for penetratin and PK-12-KKP. Also for this AMP, co-localization with markers of the 
endocytotic pathway indicated an uptake mechanism distinct from that utilized by transferrin. A small increase 
in peptide concentration would likely have revealed DRAQ7
®
 positive cells as concentrations used for 
microscopy were close to that showing toxicity using the MTS/PMS assay for this peptide. This was the most 
toxic peptide against eukaryotic cells, however, the antimicrobial potency of this peptide are in the same range as 
PK-12-KKP (E. coli 16-32 µM; S. aureus 32 µM), which is significantly lower than reported in literature (i.e. 
MICs of 1.2 µM and 0.6 µM for S. aureus and E. coli, respectively), however, different strains were tested [16]. 
The effect of the two peptides, PK-12-KKP and SA-3, on the viability of NIH 3T3 cells and HeLa WT cells were 
almost equal. When interacting with calcein-containing liposomes SA-3 completely disrupted those mimicking 
E. coli membranes, while the liposomes mimicking S. aureus membranes released ~80% of the encapsulated 
calcein. By contrast, SA-3 induced only ~33% disruption of the liposomes mimicking eukaryotic membranes. 
Thus, despite a relatively high release, this indicates that SA-3 displays some degree of selectivity towards 
bacterial membrane compositions. Comparison of the calcein release kinetics of SA-3 interacting with liposomes 
mimicking S. aureus with that of penetratin revealed an immediate onset of membrane disruption, with a critical 
concentration of SA-3 of 0.1 µM, in contrast to the slower release triggered by penetratin. While SA-3 shows 
capacity for eukaryotic internalization its significant effect on cellular viability is problematic in relation to a 
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potential use against internalized bacteria. Nevertheless, the indication of secondary structure and its apparent 
selectivity towards bacterial membranes suggest that SA-3 may constitute a useful design template allowing for 
optimization of cellular uptake over cytotoxicity. 
The peptidomimetic tritrpticin analog TPk exhibited ~50% uptake efficiency compared to penetratin and slightly 
lower than that of SA-3. The relatively high uptake of TPk is likely a result of its high content of cationic and 
non-polar amino acids. The intracellular localization of this peptidomimetic was marginally more pervasive than 
seen for the other peptides. However, there was still a clear punctate intracellular distribution, but with 
significantly less co-localization with dextran as compared to that observed for the other peptides. This could 
indicate that TPk is trafficked to a different subcellular localization or that there is loss of peptide into the 
cytosol via endosomal escape. No clear secondary structure was apparent from the CD spectra of TPk. The 
antimicrobial activity of TPk was up to 4-fold higher than that of the other tested AMPs. However, these MIC 
values are higher than what was reported in the literature, by Zhu and coworkers [17] who determined inhibitory 
concentrations of 2 µM for E. coli (KCTC 1682) and 1 µM for S. aureus (KCTC 1261) in a 1% (w/v) peptone 
solution. Surprisingly, TPk only gave rise to a minor calcein leakage when tested at 1.6 µM on the membrane 
model of S. aureus, releasing 32.5% of the encapsulated calcein, which is less than the release induced by both 
SA-3 (P<0.001) and penetratin (P<0.001), and only slightly higher than that of PK-12-PPK (P<0.001). From the 
liposomes mimicking E. coli membranes only 2.7% calcein were released, and the peptide was thus practically 
inactive towards this membrane model, while the in vitro antibacterial activity was pronounced. This confirms 
that the antibacterial effects do not rely exclusively on membrane disruption involving phospholipids. The 
interaction of TPk with the eukaryotic membrane model gave results comparable to those of the other AMPs. 
Moreover, TPk had a less negative effect on the viability of the three cell lines as compared to SA-3, but overall 
it was more membrane-disrupting than PK-12-KKP and penetratin. Zhu and coworkers reported an EC50 value 
>100 µM for TPk when assayed for viability of both HeLa and NIH 3T3 cells as determined by the MTT assay 
[17], which is in agreement with our findings for NIH 3T3 cells, but somewhat higher than the 41 µM towards 
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HeLa cells found in the present study. The intermediate uptake efficiency and notable effect on viability are less 
desirable for this peptide as a lead candidate aiming at targeting intracellular infections, but a high antimicrobial 
effect and enhanced selectivity increases its potential value as a template for further optimization.  
CONCLUSION 
In summary, the present study reports on the applicability of three different AMPs for targeting intracellular 
infections. Thus, the peptides were ranked against the well-known CPP penetratin with respect to cellular uptake 
and distribution. Also, their effect on eukaryotic and prokaryotic cell viability and leakage-inducing effect on 
liposomal membranes was compared. It was shown that the uptake mechanism for all tested peptides is very 
unlikely to involve clathrin-mediated endocytosis, and that they all aside from TPk are trafficked to lysosomes. 
Furthermore, TPk showed a stronger inhibitory effect on both Gram-positive and Gram-negative bacteria as 
compared to the other tested AMPs. One of the peptides, SA-3 reported to have an intracellular target, exhibited 
potent disrupting effects on bacteria-mimicking membranes of both Gram-positive and Gram-negative bacteria. 
PK-12-KKP was found to be well tolerated in eukaryotic cell models and with good antimicrobial properties, 
however, with weak eukaryotic internalization ability. Based on these investigations, TPk appears to be the best 
candidate for further investigations as an AMP capable of targeting intracellular infections as it may potentially 
be optimized for cell-penetration yielding an effective tool for eradication of bacteria residing inside epithelial 
cells.  
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Legend to figures 
Figure 1 – Cellular uptake of three TAMRA labeled AMPs versus that of TAMRA-penetratin measured by flow 
cytometry in HeLa cells. Prior to analysis, the cells were incubated with 10 ȝM of each peptide for 1 hr at 37°C. 
The plot represents the mean of the medians of the raw data in triplicate error bars representing SD and 
normalized against the mean of penetratin. *P<0.05, **P<0.01, ***P<0.001 statistically significant differences.  
Figure 2 - Cellular distribution of three selected AMPs (PK-12-KKP, SA-3, TPk) and penetratin (Pen) (all 
TAMRA labeled). For each photo montage: Left, grayscale: peptide; middle, grayscale: dextran/transferrin; 
right, red: peptide, green: transferrin/dextran, yellow: dextran/transferrin co-localized with peptide; blue: 
DRAQ7®. Dextran: The cells were  incubated with 0.1 mg/mL dextran for 210 min and further incubated in 
media for 20 h before exposure to 10 µM peptide for 1 h (all at 37°C). Transferrin: The cells were incubated for 
50 min with 100 nM transferrin and further incubated with both 100 nM transferrin and 10 ȝM of the peptides 
for 10 min (all at 37°C). Media for all samples contained 0.3 % (v/v) DRAQ7
®
. Images are representative single 
cross sections from the middle of cells. Scale bars correspond to 10 µm. 
Figure 3 - Circular dichroism spectra of (a) PK-12-PPK; (b) SA-3; (c) TPk and (d) penetratin in TFE-water 
90:10 (solid line) or in the presence of liposomes representing the membranes of Gram-positive bacteria, 
POPG:CL (3:1 molar ratio; dashed line); Gram-negative bacteria, POPG:CL:DOPE (2:7:1 molar ratio; dotted 
line); and eukaryotic cells, POPC:cholesterol (10:1 molar ratio; dashed and dotted line). Measurements were 
performed with a peptide concentration of 10 ȝM peptide to a lipid concentration of 1 mM yielding a peptide-to-
lipid molar ratio of 1:100. 
Figure 4 – Release of calcein from liposomes consisting of POPG:CL upon incubation with the antimicrobial 
peptide, SA-3, and the cell-penetrating peptide, penetratin. Top: Time-resolved release of calcein starting within 
10 sec of peptide addition is depicted yellow: 0.1 µM; purple: 0.2µM; green: 0.4 µM; red: 0.8 µM and blue: 1.6 
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µM. Bottom: The relative release after 680 sec versus the total calcein entrapped. Each point represents the 
mean SD (n=3).
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Table I. Amino acid sequences, number or residues and molecular weight of the investigated 
peptide variants.
Compound Sequence Residues Mw Ref
PK-12-KKP KKPWWKPWWPKWKK-amide 14 2008.46 [15]
SA-3 IKWAGKWWKLFK-amide 12 1589.97 [16]
TPk VRRFkWWWkFLRR-amide* 13 1963.38 [17]
Pen RQIKIWFQNRRMKWKK-amide 16 2245.74 [18]
TAMRA-PK-12-KKP TAMRA-KKPWWKPWWPKWKK-amide 14 2420.89
TAMRA-SA-3 TAMRA-IKWAGKWWKLFK-amide 12 2002.40
TAMRA-TPk TAMRA-VRRFkWWWkFLRR-amide 13 2375.81
TAMRA-Pen TAMRA-RQIKIWFQNRRMKWKK-amide 16 2658.17
*k refers to NLys [H2N-(CH2)4-NH-CH2-COOH].
Table 1
Click here to download Table: Table 1.docx 
Table II – Viability of mammalian cells and minimal inhibitory concentrations
Eukaryotic cell viability
a
MIC  (µM)
NIH 3T3 HUVEC HeLa WT
S. aureus
b
E. coli
c
PK-12-KKP >256 >256 >256 32 16-32
SA-3 30 ± 4.5 128-256
#
27 ± 1.7 32 16-32
TPk 128-256
#
>256 41 ± 4.0 8-16 2
Pen >256 >256 >256 32 8-16
a 
EC50 values are given in µM (n=3 in 3 passages; mean±SD) as the concentration required to give a 50% 
reduction in viability of the cells after incubation with peptide for 1 h. 
#
EC50 listed as an interval as the 
value was too close to the maximum concentration to allow accurate fitting.
b 
Strain: ATCC 25923. 
c
Strain: ATCC 25922.
Table 2
Click here to download Table: Table 2.docx 
Table III – Maximum calcein release after exposure to a concentration of 1.6 μM peptide expressed as percent 
of total amount of calcein released (mean SD).
POPG:CL (3:1)
a
S. aureus model
POPG:CL:DOPE (2:7:1)
b
E. coli model
POPC:cholesterol 
(10:1)
c
Eukaryotic model
PK-12-PPK 23.6 ± 6.1* 13.1 ± 1.7 24.3 ± 2.4
SA-3 82.2 ± 1.4 101.7 ± 1.7 33.2 ± 2.2
TPk 32.5 ± 1.3 2.7 ± 0.5 36.6 ± 4.5
Pen 99.6 ± 0.6 13.3 ± 1.4 8.4 ± 0.8
a
S. aureus membrane model, (n=3) 
b
E. coli membrane model, (n=2), 
c
Eukaryotic membrane model (n=3). Run 
time 680 sec; *Run time 340 sec. 
Table 3
Click here to download Table: Table 3.docx 
 Figure 1
Click here to download high resolution image
Figure 2
Click here to download high resolution image
Figure 3
Click here to download high resolution image
Figure 4
Click here to download high resolution image
